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Abstract
Metadherin (MTDH, also known as AEG-1, and Lyric) has been demonstrated to play a potential role in several significant
aspects of tumor progression. It has been reported that overexpression of MTDH is associated with progression of disease
and poorer prognosis in breast cancer. However, there are no studies to date assessing variants of the MTDH gene and their
potential relationship with breast cancer susceptibility. Thus, we investigated all variants of the MTDH gene and explored
the association of the variants with breast cancer development. Our cohort consisted of full-length gene sequencing of 108
breast cancer cases and 100 healthy controls; variants were detected in 11 breast cancer cases and 13 controls. Among the
variants detected, 9 novel variants were discovered and 2 were found to be associated with the susceptibility of breast
cancer. However, additional studies need to be conducted in larger sample sizes to validate these findings and to further
investigate whether these variants are prognostic in breast cancer patients.
Citation: Liu X, Zhang N, Li X, Moran MS, Yuan C, et al. (2011) Identification of Novel Variants of Metadherin in Breast Cancer. PLoS ONE 6(3): e17582. doi:10.1371/
journal.pone.0017582
Editor: Maria Castro, University of California, Los Angeles, and Cedars-Sinai Medical Center, United States of America
Received October 24, 2010; Accepted February 7, 2011; Published March 8, 2011
Copyright:  2011 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project is supported by the Program for New Century Excellent Talents in University, the Key Project of Chinese Ministry of Education (No. 108080),
the National Natural Science Foundation of China (No. 30772133; No. 81072150) and the Independent Innovation Foundation of Shandong University (IIFSDU,
No. 2009JQ007) to Prof. Q. Yang. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: qifengy@gmail.com
. These authors contributed equally to this work.
Introduction
Metadherin (MTDH, also known as AEG-1, and Lyric), was
first reported in 2002 as a novel late response gene following HIV-
1 infection or treatment with recombinant HIV-1 envelope
glycoprotein (gp120) [1]. The full-length cDNA has subsequently
been independently cloned by four different groups of investigators
[2,3,4,5]. A ‘‘lung homing domain’’, which mediates lung
metastasis in the 4T1 mouse mammary tumor cell, was identified
in MTDH in 2004 with phage display screening and was
subsequently named metadherin [4]. In addition, the mouse-rat
MTDH was also found to serve as a junction protein [5] and was
found to be located in the cytoplasm, endoplasmic reticulum,
perinuclear regions, and nucleolus [3].
Kang and colleagues first cloned and characterized the human
full-length MTDH gene; it was found to encode a single-pass
transmembrane protein with a calculated molecular mass of
64 KDa, containing 12 exons and 11 introns with a full-length of
86,082 bp, and a cDNA of 3611 bp (excluding the poly-A tail) [2].
Subsequently, the human MTDH gene was localized at
chromosome 8q22 and has been reported to be amplified in a
number of malignancies such as malignant glioma [6], hepatocel-
lular carcinoma (HCC)[7], and breast cancer [8,9,10]. Our group
has also previously published on MTDH, using computational
algorithms to establish the overexpression of MTDH in breast
cancer [11].
Following its initial identification, MTDH was thought to be a
potential focus for targeted therapy based on its multi-facet roles in
regulatingcancerprogression.ThoughtheMTDH gene wascloned
only 5 years ago, this novel gene is now known to be a potent
mediator in the development of malignancies and component of
oncogenic signaling pathways. MTDH has been demonstrated to
play a role in several significant stages of tumor progression,
including transformation, initiation of apoptosis, invasion, metasta-
sis, chemoresistance and angiogenesis. Furthermore, recent studies
have established its performance in PI3K/Akt, nuclear factor kB
(NFkB), and Wnt/b-catenin signaling pathways, laying its founda-
tionas a feasible potential target, both clinically and experimentally,
for future targeted therapy development.
Since breast cancer has become the most common tumor
among women in the whole world [11], and MTDH has been
demonstrated to be critically involved in breast cancer progression
and metastasis by our group and others,[4,12,13,14,15], in this
study, we attempted to further investigate the potential role of
MTDH in breast cancer development.
Single nucleotide polymorphisms (SNP) are defined as genetic
variation in a DNA sequence of a particular gene when a single
nucleotide is altered; SNPs are usually considered to be point
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recur in a significant proportion of the population and can occur
in coded or non-coded regions, thus the variant may or may or
may not affect the function of the gene. Identification of SNPs in
the host can potentially facilitate the evaluation of the susceptibility
of cancer or predict progression of disease of response to
treatment. Here, we investigated the genetic polymorphisms in
MTDH by direct sequencing in a cohort of breast cancer cases
and controls, with the intention of discovering of novel variants
and comparing the distribution of SNP genotype frequencies of
these 2 affected vs. non-affected cohorts to determine whether
a particular SNP may influence susceptibility to breast cancer
development.
Materials and Methods
Patients and Sample
The study involved 108 breast cancer patients diagnosed with
breast cancer in Qilu Hospital (Shandong, China) between
September 2008 and April 2010. All breast cancer cases were
classified according to the WHO classification of breast tumors.
The breast cancer cohort was histologically comprised of 7 cases
of lobular carcinoma, 82 cases of ductal carcinoma and 19
classified as other malignant sub-types of breast cancer. For the
control group, 100 healthy women unaffected with breast
cancer were included to investigate SNPs as susceptibility
biomarkers. Most of the patients and controls were Han
nationality resides in Shandong Provence, China. Details of the
patient characteristics for the 2 cohorts are shown in Table 1. For
all participants in this study, written informed consent was
obtained as delineated by the protocol which was approved by
the Ethical Committee of Shandong University. All patients
donated 1.5 ml of whole blood which was stored at 280uC in our
university laboratory.
DNA extraction
DNA from each sample of whole blood was extracted with the
TIANamp Genomic DNA Kit (Tiangen, Beijing, China) as
directed in the manufacturer’s instructions. The concentration of
DNA and the purity of each sample were measured by ultraviolet
spectrophotometer (GE Healthcare, USA). DNA samples were
routinely stored at 220uC.
Sequencing analysis of human MTDH gene
The full-length MTDH gene was sequenced to investigate
genetic variants in DNA samples from the 108 cases and 100
controls. The MTDH gene was amplified with polymerase chain
reaction (PCR) prior to sequencing. In each 50 ml PCR reaction,
1 ml genomic DNA (100 ng/ml) was amplified using 1 U EasyTaq
DNA polymerase (Transgen, Beijing, China) with 4 ml of 2.5 mM
dNTPs and 2 ml of each primer. The PCR conditions were as
follows: 94uC for 5 min, 35 cycles of 94uC for 30 seconds,
individual annealing temperature for 30 seconds, 72uC for 30
seconds and a final extension step of 72uC for 10 min. The 13
primer sets of MTDH used for the amplification and sequencing
analysis are shown in Table 2 (GenBank sequence; NC_000008.10
released in JUNE 10, 2004). All sequencing data was produced by
the Genomic Analysis Facility (BioSune, Shanhai, China) and
analyzed with Meglign 7.0 and Chromas 2.33 software.
Statistical Analysis
The genotypes and allele frequencies of the known and novel
SNPs were tested for equilibrium using a validated, public
statistical web-tool based on the Hardy-Weinberg model [16]
with a p value of .0.5 cm suggesting equilibrium. The
distribution of known and novel SNPs between the case and
control groups were analyzed using chi-squared and the Fisher’s
exact test was used when one cell count was less than 5. All
Table 1. Clinical data of cases and controls.
Clinical data Cases Controls
Age (Mean6SD)
a 48.9610.4 45.268.9
rade (%)
I,II 59(79.7) _
III 15(20.3)
ER (%)
Negative 28(26.9) _
Positive 76(73.1)
PR (%)
Negative 37(35.9) _
Positive 66(64.1)
aThe Student’s t test showed no significant difference between the two groups
(p.0.05).
doi:10.1371/journal.pone.0017582.t001
Table 2. Thirteen primer sets of MTDH for PCR amplification.
No. Primer Region Sequence of primer Length
1 MTDHUTR1-F 59 UTR 59CTGGCAACTGGTAGGCACGC39 893 bp
2 MTDHUTR1-R 59GAGGGACTCGCAGGATGACG39
3 MTDH1-F Exon 1 59ACCTTCCCTGACACGCCTTTG39 852 bp
4 MTDH1-R 59CTCTACTGCCGCTCATCCCATAC39
5 MTDH2-F Exon 2 59TGTAGAAATAAGGCTCGGAGAC39 1031 bp
6 MTDH2-R 59GGCTCAAGCAATCTACCCAC39
7 MTDH34-F Exon 3&4 59CTTTGGAGCCAGACAGACCTA39 1553 bp
8 MTDH34-R 59GACTCAAGGCAGAAAGGCAAAT39
9 MTDH5-F Exon 5 59CCTAAGTCCTGGTCCCAAAT39 1101 bp
10 MTDH5-R 59GCCTGAAAGAAGAAGGTGCT39
11 MTDH6-F Exon 6 59GGCTCCACCACAAAGATTCA39 856 bp
12 MTDH6-R 59TTAATTCCCACCTTGCTCTAC39
13 MTDH7-F Exon 7 59AAAGTCTCCGTGTCAAAGTATAG39 647 bp
14 MTDH7-R 59TTTCCGAACATACAAACCAT39
15 MTDH8-F Exon 8 59GAGTGGAATCAAATGGCTAAT39 934 bp
16 MTDH8-R 59CATAGTGTCGGGCTAGTAATC39
17 MTDH9-F Exon 9 59TGTTAGCCAGGATGGTCTCG39 936 bp
18 MTDH9-R 59AAATGTCTGTTGGGTAGATGC39
19 MTDH10-F Exon 10 59GGCAATTCTCATACCTCCTC39 1154 bp
20 MTDH10-R 59ATGTCTAAGCTGTCTATCCCTT39
21 MTDH11-F Exon 11 59TGATGATTGATTTGGCTGTA39 738 bp
22 MTDH11-R 59AAAGGAAGAAAGGGCTACT39
23 MTDH12-1-F Exon 12 59AAGGAGGGAAGAAGACATAG39 1249 bp
24 MTDH12-1-R 59TCTACGCACTACAGGTTAAG39
25 MTDH12-2-F Exon 12 59AGATTGTGCCCTATCTCATCT39 1415 bp
26 MTDH12-2-R 59AGAAATTCATCCTTGGCTCT39
doi:10.1371/journal.pone.0017582.t002
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considered statistically significant. Odds ratios (OR) and 95%
confidence intervals (CIs) were calculated using unconditional
logistic regression analysis to evaluate the association between
genotype frequencies and risk of breast cancer development. The
statistical analyses were conducted using SPSS Software 17.0
(SPSS Inc. Chicago, Illinois, USA).
Results
Novel variants discovered in MTDH and the
characterization
The patients in both cohorts (affect and control) were all from
mainland China; there were no significant clinical differences (i.e.
median ages, menstrual history, body mass index [BMI] or other
related parameters) for the 2 cohorts.
Thirteen variants were detected in the control group compared
with eleven variants in the affected breast cancer cohort; of these, 9
unnamed, novel variants were discovered in sum. The distribution
of all variants in both control and case groups is displayed in
Figure 1. The novel and known variants appear to gather at both
ends of MTDH gene, with 3 novel variants displayed in the central
part of the gene in case group, but not in the control group. The 3
variants are located at exon_6 (untitled_7), exon_7 (untitled_8) and
intron_7 (untitled_9) individually.
Among all the variants detected, 3 SNPs (rs2438211, rs2449512
and rs1311) were found with complete linkage in both groups; the
sequencing chromatogram results representing the linkage are
shown in figure 2. In addition to the known SNPs, several new
SNPs were discovered: one novel variant in the flanking sequence;
one in the 59UTR; three in the 39UTR; and one in intron 11 for
the control group. Of note, the high frequency variant in the
intron 11 was also detected in the case group. Strikingly, two low
frequency novel variants were detected in case group located in
exon_6 and exon_7, respectively. The variant in exon_7 (1390
G.A, untitled_8) was a synonymous SNP while the variant in
exon_6 (1333 C.G, untitled_7) converted a Asp to Glu in the
MTDH protein. Only one patient with breast cancer carried the
SNP (G.C, untitled_9) just one nucleotide prior to exon_8, which
was against the ‘‘GT-AG rule’’ in mRNA splicing. A detailed
description and characterization of all variants identified in this
study are shown in table 3.
The relationship between SNP genotype distribution and
breast cancer susceptibility
The genotype distributions of the high frequency polymor-
phisms in the case and control groups are shown in table S1.
When analyzed separately, the untitled_3 was found to be
associated with breast cancer development significantly more
frequently in the control group (p=0.008). Furthermore, signif-
icant differences was also observed in comparing the T/T
genotype to the C/C + C/T genotypes among cases and controls
(p=0.041; OR=2.286; 95% CI: 1.054–4.995), indicating that the
homozygous T/T genotype increases the risk of breast cancer
development 2.286 times among Chinese women.
Additionally, the MTDH (1681 G.A, rs2331652) polymorphism
was also found to increase susceptibility for breast cancer devel-
opment. Amongst the case group, the A/A genotype was detected
with a higher frequency than that in the control group; however, this
difference was not statistically significant when analyzed as a separate
genotype (p=0.062). Nevertheless, when combined with the A/G
genotype, the differences between the case and control groups were
significant. (p=0.026; OR=1.915; 95% CI: 1.098–3.339). No
significant differences in the analysis were noted when the data were
re-analyzed with stratification by clinical stage and receptor status
(ER and PR), suggesting the two polymorphisms may be applied in
the generalized breast cancer population.
However, no significant correlations were noted amongst these
variants (listed in table S1) and the clinical-pathologic parameters
(age at diagnosis, pathological diagnosis, tumorsize and grade, nodal
metastasis, etc.), suggesting that these variants may not be prognostic
indicators in female breast cancer (Data not shown). The haplotype
frequency of rs2331652 and untitled_3 was listed in table S2;
however, no significant linkage was found between the two variants
which met statistical significance associated with breast cancer.
Figure 1. The distribution of detected variants of MTDH. The black blocks stand for the 12 exons and the grey blocks represent for the 39UTR
and 59UTR respectively. The red line marked the location of each variant in MTDH. A. Control group. B. Case group.
doi:10.1371/journal.pone.0017582.g001
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Recently, a number of studies have elucidated the multi-faceted role
of MTDH in tumor progression. Overexpression of MTDH has been
observed in carcinomas and has been correlated with poor clinical
outcomes [12,15]. As a gene located downstream to Ha-Ras and c-
Myc, MTDH mediates the transforming activity of both oncogenes
[17] and furthermore, is involved multiple signaling pathways
including the PI3K/Akt [17,18], nuclear factor kB(NFkB) [19], and
Wnt/b-catenin pathways [20]. Thus, MTDH regulates different
aspects of cell activity and may function as a biomarker for predicting
disease progression and responses to different treatments [21]. Given
the recent interest in the MTDH gene and its suggested important role
in the development of breast cancer, this study was conducted to
investigate both known and novel SNPs to analyze if any of these
variants of MTDH contribute to the risk of breast cancer development.
In our present study, 13 variants in control group and 11 in case
groupweredetected.Severalofthesevariantsarebeingdescribedfor
the first time in this publication. Among these novel variants,
MTDH (1333 C.G, untitled_7) polymorphismcause an Asp to Glu
conversion in MTDH protein, which may facilitate the structural
research of the protein. Interestingly, one patient with breast cancer
carried a G/C variant (C.G, untitled_9) justone nucleotide prior to
exon_8, which was against the ‘‘GT-AG rule’’ in mRNA splicing
Therefore, this single nucleotide conversion will cause the failure in
splicingofmtdhproteinandsubsequentlydysfunctionofthisprotein.
In this study, two variants were identified that were significantly
associated with increased susceptibility for breast cancer develop-
ment. Significant difference was found between case and control
group in both untitled_3 and MTDH (1681 G.A, rs2331652)
polymorphism; these variants require functional analysis and
validation in larger patient populations to confirm the correlation
to breast cancer susceptibility. Furthermore, the association of
these variants to outcomes needs to be examined to determine if
these SNPs are also prognostic indicators for disease recurrence or
progression in breast cancer patients.
As indicated previously, the participants involved in our study
were mainly residents in Shandong Province, China. Since the
Chinese population generally is genetically more homogeneous
than other ethnic populations, we predict similar findings in larger
sample sizes across China, but the applicability of our findings to
other ethnic populations (both within Asian and outside Asia) will
need further investigation in varying patient populations before
these data can be generally extrapolated to other ethnicities.
The discrepancy between the lack of correlation of the variants
in the current study to disease progression in breast cancer (data
not shown), and the previously documented [12] high MTDH
expression contributing to increased metastasis and poor prognosis
warrants further discussion. The two studies were comprised of
completely different ethnic groups (one study had U.S. citizens
with significant genetic heterogeneity, while the current study was
more homogeneous with all participants of Chinese descent); thus,
ethnicity/race may be an independent factor affecting the
association of the distribution of MTDH SNPs and breast cancer
development. This highlights the need for multi-ethnic evaluation
of MTDH in future studies.
In conclusion, in addition to finding some known variants of
MTDH, several novel SNPs of MTDH were discovered in our study
that appear to be correlated to breast cancer susceptibility Since
MTDH has been demonstrated as a key regulator in the complex
Figure 2. Sequencing chromatogram results of the complete linkage among rs2438211, rs2449512 and rs1311.
doi:10.1371/journal.pone.0017582.g002
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clarifying the functional role of this gene and its association to breast
cancer development and recurrence are needed. While additional
study on the MTDH gene is necessary, variants of MTDH may
prove to be potential markers for breast cancer development,
prognostic indicators for disease progression, and possible foci for
future targeted therapy.
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